<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genet</journal-id><journal-title>BMC Genetics</journal-title><issn pub-type="epub">1471-2156</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15331022</article-id><article-id pub-id-type="pmc">PMC515298</article-id><article-id pub-id-type="publisher-id">1471-2156-5-24</article-id><article-id pub-id-type="doi">10.1186/1471-2156-5-24</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>HLA DR phenotypic frequencies and genetic risk of Type 1 diabetes in west region of Algeria, Tlemcen</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Aribi</surname><given-names>Mourad</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>m_aribi@mail.univ-tlemcen.dz</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Moulessehoul</surname><given-names>Soraya</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s.moulessehoul@univ-sba.dz</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Benabadji</surname><given-names>Ahmed-Bakir</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>b_benabadji@mail.univ-tlemcen.dz</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Kendoucitani</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>mkendouci@mail.univ-tlemcen.dz</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biology, Djillali Liabes University, Sidi-Bel-Abb&#x000e8;s, 22 000, Algeria</aff><aff id="I2"><label>2</label>Department of Pharmacy, Abou-Bekr Belaka&#x000ef;d University, Tlemcen, 13 000, Algeria</aff><aff id="I3"><label>3</label>Department of Medicine, Internal Medicine Board, Medical Centre University of Tlemcen, 13 000, Algeria</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>24</day><month>8</month><year>2004</year></pub-date><volume>5</volume><fpage>24</fpage><lpage>24</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2156/5/24"/><history><date date-type="received"><day>7</day><month>11</month><year>2003</year></date><date date-type="accepted"><day>24</day><month>8</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Aribi et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Aribi et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Aribi
               Mourad
               
               
               m_aribi@mail.univ-tlemcen.dz
            </dc:author><dc:title>
            HLA DR phenotypic frequencies and genetic risk of Type 1 diabetes in west region of Algeria, Tlemcen
         </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>BMC Genetics 5(1): 24-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2156(2004)5:1&#x0003c;24&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2156</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The main genomic region controlling the predisposition to type 1 diabetes is the Human Leukocyte Antigens (HLA) class II of the major histocompatibility complex. Association with different HLA types depends also on the studied populations. In our investigation, we tried to measure the phenotypic HLA class II association frequencies of DR3 and/or DR4 antigens, using a serologic method called microlymphocytotoxicity analysis, in diabetic and nondiabetic (ND) subjects originating from the west-Algerian region of Tlemcen. The aim of the present study was to determine which HLA DR antigens represent a high susceptibility to develop the disease in this area. Using a case-control retrospective study design, we randomly recruited ninety-one related subjects, 39 type 1 diabetics and 52 ND as controls, at the Internal Medicine Board of Medical Centre University of Tlemcen.</p></sec><sec><title>Results</title><p>DR3 antigen frequencies were comparable between the type 1 diabetics and the ND subjects and showed no association with the disease (<italic>p </italic>= 1.000, OR = 0.95), whereas DR4 and DR3DR4 antigens were associated with susceptibility to develop type 1 diabetes (DR4; OR = 2.10, DR3DR4; OR = 1.30). Also, no incidence for DR3 (<italic>p </italic>= 0.2646) or DR3DR4 (<italic>p </italic>= 0.0699) antigen frequencies was related to the sex ratio. However, significant differences in HLA DR4 frequencies between type 1 diabetics and ND were found to be related to sex (<italic>p </italic>= 0.0085).</p></sec><sec><title>Conclusion</title><p>Taken together, our investigation showed that the strongest association with type 1 diabetes was noticed in the presence of HLA DR4 antigens followed by DR3DR4 antigens. This study highlighted a characteristic of Tlemcen population; a history of consanguineous marriages. Association studies between the disease and genetic polymorphisms should be undertaken in a population where consanguinity is more limited to reduce confounding in result interpretations.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The type 1 diabetes, previously called insulin-dependent diabetes mellitus (IDDM), is the consequence of progressive and selective destruction of pancreatic &#x003b2; cells by an immune-mediated process [<xref ref-type="bibr" rid="B1">1</xref>], resulting in an absolute lack of insulin [<xref ref-type="bibr" rid="B2">2</xref>]. It is well established that this self-destruction is primarily provoked by the activation of the autoreactive T lymphocytes by the production of T-helper 1 cytokines [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. In addition, the difference of the epidemiological data from one region to another could largely explain why the release of the autoimmunity is stimulated under the influence of one or more environmental factors [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>], in genetically predisposed subjects. It is currently obvious that the strongest genetic susceptibility of predisposition is allotted to the IDDM1 alleles located in the HLA locus of the chromosome 6p21 [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>], and the non-HLA alleles, particularly the IDDM2 polymorph gene located in the region 5' of the insulin gene (<italic>INS</italic>) promoter situated on the chromosome 11p15 [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Other regions of the genome were identified as IDDM3, coding for the IGF1 receptor, IDDM4, located near the fibroblast growth factor 3 gene, IDDM5, near the estrogens receptor gene [<xref ref-type="bibr" rid="B7">7</xref>] etc. The majority of these regions have no possible statistical criteria allowing them to be clearly linked to the disease [<xref ref-type="bibr" rid="B11">11</xref>]. In all cases, it is mainly HLA alleles that present a high risk of contracting the disease compared to non-HLA alleles [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Due to this, they are qualified as high genetic predictive markers of developing type 1 diabetes in families having a type 1 diabetic member. Interestingly, the disease prediction offered with success the possibility of clinical trials to delay, or even prevent the appearance of type 1 diabetes.</p><p>However, the different HLA types associated with diabetes depend also on the population. The purpose of our study is to measure HLA DR3 and/or DR4 antigen frequencies and their association in diabetic and nondiabetic subjects originating from the west-Algerian region of Tlemcen. Using a case-control retrospective study design, we attempt to determine which is the greatest HLA DR susceptibility contributing to developing type 1 diabetes. Ninety-one (91) eligible subjects (thirty-nine (39) type 1 diabetics and fifty-two (52) nondiabetics with relatives with type 1 diabetes as controls), were recruited at the Internal Medicine Board of the Medical Centre University of Tlemcen.</p></sec><sec><title>Results</title><p>Table <xref ref-type="table" rid="T1">1</xref> summarizes HLA DR3, DR4 and DR3DR4 antigen frequencies in type 1 diabetics and their nondiabetic relatives.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>HLA DR phenotypic frequencies according to <italic>p</italic>-values and Odds ratio in type 1 diabetic and nondiabetic subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><bold>Type 1 diabetics n = 39: 15 M/24 F</bold></td><td align="center" colspan="2"><bold>Nondiabetic controls n = 52: 21 M/31F</bold></td><td></td><td></td></tr><tr><td></td><td colspan="4"><hr></hr></td><td></td><td></td></tr><tr><td></td><td align="center" colspan="4"><bold>Frequency (Proportion and %)</bold></td><td></td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td></tr><tr><td align="left"><bold>HLA</bold></td><td align="center"><bold>M</bold></td><td align="center"><bold>F</bold></td><td align="center"><bold>M</bold></td><td align="center"><bold>F</bold></td><td align="center"><bold><italic>p</italic></bold></td><td align="center"><bold>Odds ratio (95 % CI)</bold></td></tr></thead><tbody><tr><td align="left"><bold>DR3</bold></td><td align="center">3 (7.69)</td><td align="center">7 (17.9)</td><td align="center">5 (9.62)</td><td align="center">9 (17.31)</td><td align="center">0.2646<sup>a</sup></td><td align="center">0.95 (0.48&#x02013;1.87)</td></tr><tr><td></td><td align="center" colspan="2">10 (25.64)</td><td align="center" colspan="2">14 (26.92)</td><td align="center">1.000</td><td></td></tr><tr><td align="left"><bold>DR4</bold></td><td align="center">4 (10.26)</td><td align="center">9 (23.08)</td><td align="center">6 (11.54)</td><td align="center">4 (7.69)</td><td align="center">0.0085 <sup>a, </sup>*</td><td align="center">2.10 (1.04&#x02013;4.24)</td></tr><tr><td></td><td align="center" colspan="2">13 (33.33)</td><td align="center" colspan="2">10 (19.23)</td><td align="center">0.0361*</td><td></td></tr><tr><td align="left"><bold>DR3DR4</bold></td><td align="center">4 (10.26)</td><td align="center">4 (10.26)</td><td align="center">2 (3.85)</td><td align="center">7 (13.46)</td><td align="center">0.0699<sup>a</sup></td><td align="center">1.30 (0.60&#x02013;2.80)</td></tr><tr><td></td><td align="center" colspan="2">8 (20.51)</td><td align="center" colspan="2">9 (17.31)</td><td align="center">0.5887</td><td></td></tr><tr><td align="left"><bold>DR3 and/or DR4</bold></td><td align="center">11 (28.21)</td><td align="center">20 (51.28)</td><td align="center">13 (25.0)</td><td align="center">20 (38.46)</td><td align="center">0.5791<sup>a</sup></td><td align="center">2.21 (1.13&#x02013;4.36)</td></tr><tr><td></td><td align="center" colspan="2">31 (79.49)</td><td align="center" colspan="2">33 (63.46)</td><td align="center">0.0194*</td><td></td></tr><tr><td align="left"><bold>X/X</bold></td><td align="center">4 (10.26)</td><td align="center">4 (10.26)</td><td align="center">8 (15.38)</td><td align="center">11 (21.15)</td><td align="center">0.0111 <sup>a, </sup>*</td><td align="center">-</td></tr><tr><td></td><td align="center" colspan="2">8 (20.51)</td><td align="left" colspan="2">19 (36.54)</td><td align="left">0.0194*</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>p</italic>-Values related to the sex ratio comparison (male = M, female = F). * <italic>p </italic>&#x0003c; 0.05. X = non-DR3, non-DR4.</p></table-wrap-foot></table-wrap><p>DR4 and DR3DR4 antigens showed an association with susceptibility to type 1 diabetes (DR4; OR = 2.10, DR3DR4; OR = 1.30, that is respectively OR confidence interval 1.04&#x02013;4.24 and 0.60&#x02013;2.80, 95% CI), in contrast, DR3 antigens showed no association with the disease (OR = 0.95, OR confidence interval 0.48&#x02013;1.87, 95% CI). It is important to notice that the strongest association is found in DR4 phenotype as indicated in Figure <xref ref-type="fig" rid="F1">1</xref>.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>HLA DR antigen associations with type 1 diabetes. </bold>The block boxes represent the odds ratios (OR). The horizontal lines represent the lower and upper confidence limit of OR (confidence interval, 95 % CI).</p></caption><graphic xlink:href="1471-2156-5-24-1"/></fig><p>In addition, the phenotypic frequency of DR4 or DR3DR4 molecules is higher in diabetic group than in the control one, although the difference did not reach significance level in DR3DR4 frequencies (<italic>p </italic>= 0.0361 and <italic>p </italic>= 0.5887 respectively). On the contrary, the DR3 molecules frequency is slightly decreased in type 1 diabetic patients compared to the controls and presents no statistically significant difference (<italic>p </italic>= 1.000). Furthermore, no incidence was related to the sex criteria for the frequencies of DR3 and DR3DR4 molecules (<italic>p </italic>&#x0003e; 0.05). However, significant differences in HLA DR4 frequencies are linked to the female sex and present a value definitely higher in type 1 diabetic patients compared to those of nondiabetics for the same sex (<italic>p </italic>&#x0003c; 0.05) (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>HLA DR antigen frequencies compared to the sex ratio. </bold>* <italic>p </italic>&#x0003c; 0.05, Type 1 diabetics vs. control subjects.</p></caption><graphic xlink:href="1471-2156-5-24-2"/></fig></sec><sec><title>Discussion</title><p>Type 1 diabetes is a polygenic disease which results from the interaction between environmental (viral, toxic, nutritional, socioeconomic [<xref ref-type="bibr" rid="B6">6</xref>]) and genetic factors. It is the form of diabetes which occurs mainly in children and young adults [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>Fortunately, molecular epidemiology offers the hope of the possibility of preventing the disease in the future, by evaluating the potential factors of risk of developing this pathology [<xref ref-type="bibr" rid="B6">6</xref>]. Although almost 90 % of new cases of type 1 diabetes occur sporadically, studies of individuals with a diabetic relative in their family are essential [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>It is well established that associations between type 1 diabetes and certain HLA antigens largely facilitate the identification of the subjects having a potential risk to develop the disease. Among the putative HLA molecules known to confer a high susceptibility are DQA1 (*0301)-DQB1 (*0302) (= DQ8), DQA1 (*0501)-DQB1 (*0201) (= DQ2), DRA-DRB1 (*0401) (= DR4) and DRA-DRB1 (*0301) (= DR3) [<xref ref-type="bibr" rid="B14">14</xref>]. However, epidemiological studies showed that the different HLA types associated with the diabetes depend also on the various populations. For instance, the risk of developing type 1 diabetes in Caucasians is greater if they are carrying the HLA A8 and B15, while DQ6 alleles are protectors [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Among Japanese, it is the association with the HLA B54 that confers a higher susceptibility to develop the disease, while the strongest association was found with HLA DR and HLA DQ locus [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>In Algeria, and especially in its western region (Tlemcen), which is known for its history of consanguineous marriage, there is a high rate of consanguinity. This fact could increase the risk of developing type 1 diabetes by favouring the transmission of HLA haplotypes and recessive genes of susceptibility except for HLA antigens that are common in both parents. For these reasons, we were interested in checking whether phenotypically DR3DR4 antigens would involve less risk to develop the disease, in comparison with DR3 or DR4 antigens, knowing the fact that the presence of a probable consanguinity could reduce the frequency of DR3DR4 polymorph phenotype compared to that of DR3 or DR4 phenotype.</p><p>On a purely comparative basis, similarities seem to be found between our results and those of other investigators [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B15">15</xref>] with regards to HLA DR4 or DR3DR4 frequencies, which are higher in the type 1 diabetic than the nondiabetic population. On the contrary, the HLA DR3 antigens showed comparable frequencies in both groups of our sample. Consequently, these observations associating DR3 phenotype to a protector effect against type 1 diabetes in our studied population are thus do not conform with those reported in the literature [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. However, DR4 and DR3DR4 antigens are obviously associated with susceptibility of developing the disease. It should also be noted that DR3DR4 antigens might represent a weaker predictive value of disease risk. We concluded from this that the non-excess of DR3DR4 antigens, or comparable frequencies of DR3 molecules between type 1 diabetic patients and ND relative controls, might be a strong indices of consanguinity in our sample. A recent study carried out in Sweden showed that HLA DR3 is associated to the development of type 1 diabetes and the incompatibility of blood group ABo [<xref ref-type="bibr" rid="B19">19</xref>]. One can thus note that the role of the HLA DR3 antigens in conferring risk for type 1 diabetes can be masked in the homogeneous populations. Due to the restricted size of our sample, which may influence our interpretation, we should not consider the odds ratio of HLA DR3 antigens or the eventual consanguinity of our studied population. Moreover, many evidences [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B23">23</xref>] incriminate DR3 and/or DR4 antigens in the susceptibility to type 1 diabetes and their association with the detected autoantibodies in this disease. Indeed, the marks of autoimmunity are much more observed in the diabetic patients carrying DR3 or DR4 antigens than in the diabetic patients where DR3 or DR4 antigens were absents [<xref ref-type="bibr" rid="B13">13</xref>]. Furthermore, recent research indicates that a subject with HLA DR4 or DR3 alleles has three or four times more chance of developing type 1 diabetes compared to the general population; DR3DR4 is associated with the highest risk (20 to 40 times more) [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>In Algeria, very few investigations have been undertaken to study the impact of the genetic background on the risk to develop type 1 diabetes in its population, where an annual average incidence of 4.7 per 100000 has already been listed [<xref ref-type="bibr" rid="B24">24</xref>]. In a similar study carried out on Algerian unrelated type 1 diabetics (n = 50) and nondiabetics controls (n = 46), the presence of DR3-DQ2 (linkage disequilibrium) in 45 % of patients and in 13 % of controls was detected by molecular genotyping method using PCR (polymerase chain reaction) and SSO (sequence specific oligonucleotide). DR4-DQ8 was found in 37 % of diabetic cases and in 4 % of control groups [<xref ref-type="bibr" rid="B25">25</xref>]. Finally, association with type 1 diabetes attributed to DR-B1*0405 (alleles of DR4 antigens expression) susceptibility showed a match with our results; however, the DR4 antigens were found to be linked to the female sex. According to the results showed in Table <xref ref-type="table" rid="T1">1</xref>, there is no difference between men and women patients with type 1 diabetes carrying DR4 antigens, but a significant difference was noticed in female sex, either women were contracted or not with diabetic disease.</p><p>It is certain that screening of HLA class II sub-types and determination of DNA coding sequences allows more precise characterization of ethnic groups, especially, because the same coded molecules can differ by the position of few amino acids. For example, it is well established that DQA1 and DQB1 alleles (sub-types of HLA DQ) code respectively for the alpha and beta chain of the DQ molecule [<xref ref-type="bibr" rid="B6">6</xref>]. Thus, the combination of DQ alpha with Arg in position 52 (Arg-52) and DQ beta in position 57 without Asp (non-Asp 57) is called a diabetogenic heterodimer which is the biggest risk factor of type 1 diabetes in Caucasian. Nevertheless, among the Japanese population, type 1 diabetes is particularly associated with HLA DQ alpha Arg-52, but not with HLA DQ beta non-Asp 57 [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Moreover, it is true that the search of an association with a candidate gene allows a better characterization for most of the frequent multifactorial diseases, because the candidate genes are directly implied in the pathological processes. Today, it is reported that the CTLA-4 (cytotoxic T-lymphocyte antigen-4) allele, localised on the chromosome 2p33, former IDDM12, is largely associated with the susceptibility of numerous common complex diseases, such as the common autoimmune disorders Graves' disease, the autoimmune hypothyroidism and type 1 diabetes [<xref ref-type="bibr" rid="B26">26</xref>]. Combined, these pertinent observations still open new perspectives for debating this crucial subject concerning the public health.</p></sec><sec><title>Conclusion</title><p>Type 1 diabetes, or youth diabetes, is a multifactorial disease occurring on a genetic ground of predisposition and starts under certain environmental conditions. The most effective preventive strategy must be designed at the pre-diabetes stage, since immune and/or genetic markers can easily indicate subjects with high risk before the clinical symptoms. Thus, the genetic analysis of HLA class II associations has allowed a screening of the contributing molecules to the type 1 diabetes development and the selection of subjects, which are likely to contract the disease.</p><p>In this study, we were confronted with difficulties in interpretation of our results which are mainly due to the presence of some indices of consanguinity in our studied population, showing a non excess of DR3DR4 phenotype compared to the DR3 or DR4 phenotype, and a no link of DR3 phenotype to the disease. This result could be due to an ethnic characteristic of Tlemcen population, a history of consanguineous marriages. Nevertheless, these preliminary results made it possible to answer the asked questions. Thus, the strongest type 1 diabetes association is statistically revealed with phenotypic expression of DR4 followed by DR3DR4 phenotype. Association studies between the disease and genetic polymorphisms should be carried out on the population having more limited consanguinity to reduce confusions in result interpretations.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>The study was conducted on ninety-one first-degree related subjects (brothers, sisters and siblings), randomly recruited at the Internal Medicine Board of the Medical Centre University of Tlemcen (west-Algeria). The sample included thirty-nine patients with type 1 diabetes (15 males, 24 females), and fifty-two healthy subjects (21 males, 31 females) selected from diabetes relatives as controls. Prior medical histories and personal characteristics were obtained from participants <italic>via </italic>a questionnaire. The patients' mean (&#x000b1; Standard Deviation) age at clinical onset was 12.28 &#x000b1; 5.97 years with range of 5 to 22 years and median of 11 years. Subjects who were not first degree related and who were not originating from Tlemcen region were excluded. The use of first-degree relatives eliminates exposures of environmental factors such as food items and viruses since first-degree relatives usually share the same milieu. For execution of the protocol, the informed consent was obtained from all the participating subjects to the designated study.</p></sec><sec><title>HLA phenotyping (standard complement-dependent assay)</title><p>The applied serologic technique lies on the aptitude of the antibodies to recognize allotropic determinants of HLA molecules on cellular surface [<xref ref-type="bibr" rid="B27">27</xref>]. This method is sensitized by a reaction of microlymphocytotoxicity [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>], which uses specific anti-HLA DR antisera and rabbit complement of commercial typing tray (Biotest, Germany). Initially, the peripheral blood lymphocytes (PBL) were separated from the other illustrated elements of venous blood (collected in EDTA-containing tubes) by density gradient centrifugation on Ficoll-Hypaque [<xref ref-type="bibr" rid="B30">30</xref>]. B lymphocytes were isolated by using nylon-wool-separated columns [<xref ref-type="bibr" rid="B31">31</xref>].</p></sec><sec><title>Statistical analysis</title><p>The comparison of phenotypic frequencies was obtained by using chi-square analysis with Yates' correction or by Fisher's Exact test, whenever appropriate. The application of the observed &#x003c7;<sup>2 </sup>vs. expected &#x003c7;<sup>2 </sup>was employed to show significance of frequency differences with the sex ratio. A <italic>p </italic>value of less than 0.05 was considered statistically significant (two-by-two table: degrees of freedom (df) = 1, chi-square &#x02265; 3.84) [<xref ref-type="bibr" rid="B32">32</xref>]. The association between HLA antigens and type 1 diabetes was performed by determination of odds ratio (OR) [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>] (confidence interval, 95 % CI). All statistical analyses were performed using the Epi Info 2000 Version 1.0 for Windows 95, 98, NT, and 2000 computers (Epi Info, Atlanta, Georgia, USA) and STATISTICA Version 5.0, '97 (STATISTICA, StatSoft, Paris, France).</p></sec></sec><sec><title>Author's contributions</title><p>AM drafted the manuscript, performed statistical analyses and carried out the bibliography research. MS participated by coordinating and orienting the designated study. BA carried out HLA phenotyping and participated in the study design. KM recruited the eligible subjects. All authors read and approved the final version of the manuscript.</p></sec></body><back><ack><sec><title>Acknowledgments</title><p>The authors would like to express their deep recognition and greatest thanks to Professor Kaoual Meguenni, Head of the Epidemiology Board (Medical Centre University of Tlemcen) for his precious assistance and using data processing materials of his Board. They are also indebted to Dr Malika Bendahmane for critically reading the manuscript. They are grateful to the staff of Immunology and Hematology Boards of the Medical Centre University staff of Tlemcen for their collaboration and technical assistance, and to the Scientific and Technical Research Centre (SERIST) staff of Tlemcen for their documentary assistance in this study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorus</surname><given-names>FK</given-names></name><name><surname>Vandewalle</surname><given-names>CL</given-names></name><name><surname>Winnock</surname><given-names>F</given-names></name><name><surname>Lebleu</surname><given-names>F</given-names></name><name><surname>Keymeulen</surname><given-names>B</given-names></name><name><surname>Van der Auwera</surname><given-names>B</given-names></name><name><surname>Falorni</surname><given-names>A</given-names></name><name><surname>Dorchy</surname><given-names>H</given-names></name><name><surname>F&#x000e9;ry</surname><given-names>F</given-names></name><name><surname>Pipeleers</surname><given-names>DG</given-names></name><collab>the Belgian Diabetes Registry</collab></person-group><article-title>Increased prevalence of abnormal immunoglobulin M, G, and A concentrations at clinical onset of insulin-dependent diabetes mellitus: a registry-based study</article-title><source>Pancreas</source><year>1998</year><volume>1</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">9436863</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erba&#x0011f;ci</surname><given-names>AB</given-names></name><name><surname>Tarak&#x000e7;io&#x0011f;lu</surname><given-names>M</given-names></name><name><surname>Co&#x0015f;kun</surname><given-names>Y</given-names></name><name><surname>Sivasli</surname><given-names>E</given-names></name><name><surname>Namiduru</surname><given-names>ES</given-names></name></person-group><article-title>Mediators of inflammation in children with type 1 diabetes mellitus: cytokines in type 1 diabetic children</article-title><source>Clin Biochem</source><year>2001</year><volume>34</volume><fpage>645</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11849625</pub-id><pub-id pub-id-type="doi">10.1016/S0009-9120(01)00275-2</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>NJ</given-names></name><name><surname>Van Gunst</surname><given-names>K</given-names></name><name><surname>Sarvetnick</surname><given-names>N</given-names></name></person-group><article-title>Th1 and Th2 pancreatic inflammation differentially affect homing of islet-reactive CD4 cells in nonobese diabetic mice</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><fpage>1649</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">12574327</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kulmala</surname><given-names>P</given-names></name><name><surname>Savola</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>JS</given-names></name><name><surname>V&#x000e4;h&#x000e4;salo</surname><given-names>P</given-names></name><name><surname>Karjalainen</surname><given-names>J</given-names></name><name><surname>L&#x000f6;pp&#x000f6;nen</surname><given-names>T</given-names></name><name><surname>Dyrberg</surname><given-names>T</given-names></name><name><surname>&#x000c5;kerblom</surname><given-names>HK</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name><collab>Childhood Diabetes in Finland Study Group</collab></person-group><article-title>Prediction of Insulin-dependent Diabetes Mellitus in Siblings of Children with Diabetes. A population-based Study</article-title><source>J Clin Invest</source><year>1998</year><volume>2</volume><fpage>327</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">9435304</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kida</surname><given-names>K</given-names></name><name><surname>Kaino</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Hirai</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name></person-group><article-title>Immunogenetics of insulin-dependent diabetes mellitus</article-title><source>Acta P&#x000e6;diatr</source><year>1999</year><volume>Suppl 427</volume><fpage>3</fpage><lpage>7</lpage></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorman</surname><given-names>J</given-names></name><collab>the WHO DiaMon Molecular Epidemiologie Sub-Project Group</collab></person-group><article-title>Molecular Epidemiology of Insulin-dependent Diabetes Mellitus: WHO Diamon Project</article-title><source>Gac M&#x000e9;d M&#x000e9;x</source><year>1997</year><volume>Suppl 1</volume><fpage>151</fpage><lpage>4</lpage></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bourcigaux</surname><given-names>N</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name></person-group><article-title>Diab&#x000e8;te insulino-d&#x000e9;pendant: Etiologie, physiopathologie, diagnostic, complications, pronostic, traitement</article-title><source>La Revue du Praticien</source><year>1997</year><volume>47</volume><fpage>1583</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">9366118</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>FW</given-names></name><name><surname>Norris</surname><given-names>JM</given-names></name><name><surname>Kolb</surname><given-names>H</given-names></name></person-group><article-title>Milk and type 1 diabetes</article-title><source>Diabetes Care</source><year>1996</year><volume>19</volume><fpage>379</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8729165</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akerblom</surname><given-names>HK</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name></person-group><article-title>From pathomecanisms to prediction, prevention and improved care of insulin-dependent diabetes mellitus in children</article-title><source>Ann Med</source><year>1997</year><volume>29</volume><fpage>383</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">9453284</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vandewalle</surname><given-names>CL</given-names></name><name><surname>Falorni</surname><given-names>A</given-names></name><name><surname>Lernmark</surname><given-names>&#x000c5;</given-names></name><name><surname>Goubert</surname><given-names>P</given-names></name><name><surname>Dorchy</surname><given-names>H</given-names></name><name><surname>Coucke</surname><given-names>W</given-names></name><name><surname>Semakula</surname><given-names>C</given-names></name><name><surname>Van der Auwera</surname><given-names>B</given-names></name><name><surname>Kaufman</surname><given-names>L</given-names></name><name><surname>Schuit</surname><given-names>FC</given-names></name><name><surname>Pipeleers</surname><given-names>DG</given-names></name><name><surname>Gorus</surname><given-names>FK</given-names></name><collab>the Belgian Diabetes Registry</collab></person-group><article-title>Associations of GAD-65 and IA-2-autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings</article-title><source>Diabetes Care</source><year>1997</year><volume>10</volume><fpage>1547</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9314633</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiwa</surname><given-names>F</given-names></name></person-group><article-title>Diabetes in the 1990s-an overview</article-title><source>Statistical Bulletin</source><year>1997</year><volume>Jan&#x02013;Mar</volume><fpage>2</fpage><lpage>8</lpage></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nepom</surname><given-names>GT</given-names></name></person-group><article-title>Immunogenetics and IDDM</article-title><source>Diabetes Rev</source><year>1993</year><volume>1</volume><fpage>93</fpage><lpage>03</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>JF</given-names></name></person-group><article-title>L'origine immunitaire du diab&#x000e8;te</article-title><source>La Recherche</source><year>1989</year><volume>214</volume><fpage>1206</fpage><lpage>15</lpage></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Honeyman</surname><given-names>M</given-names></name><name><surname>Wasserfall</surname><given-names>C</given-names></name><name><surname>Nerup</surname><given-names>J</given-names></name><name><surname>Rossini</surname><given-names>A</given-names></name></person-group><article-title>Prediction and prevention of IDDM</article-title><source>Diabetologia</source><year>1997</year><volume>40</volume><fpage>B58</fpage><lpage>B61</lpage><pub-id pub-id-type="pmid">9345647</pub-id><pub-id pub-id-type="doi">10.1007/s001250051403</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amirzargar</surname><given-names>A</given-names></name><name><surname>Mostafavi</surname><given-names>H</given-names></name><name><surname>Farjadian</surname><given-names>Sh</given-names></name><name><surname>Ghaderi</surname><given-names>A</given-names></name></person-group><article-title>Association of HLA-class II alleles and susceptibility to type 1 diabetes in southern Iranian patients</article-title><source>Irn J Med Sci</source><year>2000</year><volume>25</volume><fpage>109</fpage><lpage>13</lpage></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>AP</given-names></name><name><surname>Louzada-Junior</surname><given-names>P</given-names></name><name><surname>Foss</surname><given-names>MC</given-names></name><name><surname>Donadi</surname><given-names>EA</given-names></name></person-group><article-title>HLA-DRB1, DQB1, and DQA1 allele profile in Brazilian patients with type 1 diabetes mellitus</article-title><source>Ann N Y Acad Sci</source><year>2002</year><volume>958</volume><fpage>305</fpage><lpage>08</lpage><pub-id pub-id-type="pmid">12021129</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petrone</surname><given-names>A</given-names></name><name><surname>Bugawan</surname><given-names>TL</given-names></name><name><surname>Mesturino</surname><given-names>CA</given-names></name><name><surname>Nistico</surname><given-names>L</given-names></name><name><surname>Galgani</surname><given-names>A</given-names></name><name><surname>Giorgi</surname><given-names>G</given-names></name><name><surname>Cascino</surname><given-names>I</given-names></name><name><surname>Erlich</surname><given-names>HA</given-names></name><name><surname>Di Mario</surname><given-names>U</given-names></name><name><surname>Buzzetti</surname><given-names>R</given-names></name></person-group><article-title>The distribution of HLA class II susceptible/protective haplotypes could partially explain the low incidence of type 1 diabetes in continental Italy (Lazio region)</article-title><source>Tissue Antigens</source><year>2001</year><volume>58</volume><fpage>385</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">11929589</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.2001.580607.x</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richens</surname><given-names>ER</given-names></name><name><surname>Shaltout</surname><given-names>A</given-names></name><name><surname>Bahr</surname><given-names>GM</given-names></name><name><surname>Abdella</surname><given-names>N</given-names></name><name><surname>Jayyab</surname><given-names>AK</given-names></name><name><surname>Al-Saffar</surname><given-names>M</given-names></name><name><surname>Behbehani</surname><given-names>K</given-names></name></person-group><article-title>Insulin binding substances, autoimmunity and type I diabetes in Kuwaiti patients and their kindred</article-title><source>Acta Diabetol Lat</source><year>1989</year><volume>26</volume><fpage>115</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">2789462</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berzina</surname><given-names>L</given-names></name><name><surname>Ludvigsson</surname><given-names>J</given-names></name><name><surname>Sadauskaite-Kuehne</surname><given-names>V</given-names></name><name><surname>Nelson</surname><given-names>N</given-names></name><name><surname>Shtauvere-Brameus</surname><given-names>A</given-names></name><name><surname>Sanjeevi</surname><given-names>CB</given-names></name></person-group><article-title>DR3 is associated with type 1 diabetes and blood group ABO incompatibility</article-title><source>Ann N Y Acad Sci</source><year>2002</year><volume>958</volume><fpage>345</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">12021139</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Honeyman</surname><given-names>MC</given-names></name><name><surname>Harrison</surname><given-names>LC</given-names></name><name><surname>Drummond</surname><given-names>B</given-names></name><name><surname>Colman</surname><given-names>PC</given-names></name><name><surname>Tait</surname><given-names>BD</given-names></name></person-group><article-title>Analysis of families at risk for IDDM reveals that HLA antigens influence progression to clinical disease</article-title><source>Mol Med</source><year>1995</year><volume>1</volume><fpage>576</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">8529124</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deschamps</surname><given-names>I</given-names></name><name><surname>Boitard</surname><given-names>C</given-names></name><name><surname>Hors</surname><given-names>J</given-names></name><name><surname>Busson</surname><given-names>M</given-names></name><name><surname>Marcelli-Barge</surname><given-names>A</given-names></name><name><surname>Mogenet</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>JJ</given-names></name></person-group><article-title>Life table analysis of the risk of type 1 (insulin-dependent) diabetes mellitus in sibling according to islet cell antibodies and HLA markers. An 8-year prospective study</article-title><source>Diabetologia</source><year>1992</year><volume>35</volume><fpage>951</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">1451952</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owerbach</surname><given-names>D</given-names></name><name><surname>Gum</surname><given-names>S</given-names></name><name><surname>Gabbay</surname><given-names>KH</given-names></name></person-group><article-title>Primary association of HLA-DQ<sub>W</sub>8 whith type 1 diabetes mellitus in DR4 patients</article-title><source>Diabetes</source><year>1989</year><volume>38</volume><fpage>942</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">2786821</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Genovese</surname><given-names>S</given-names></name><name><surname>Bonfanti</surname><given-names>R</given-names></name><name><surname>Bazzigallupi</surname><given-names>E</given-names></name><name><surname>Lampasona</surname><given-names>V</given-names></name><name><surname>Banazzi</surname><given-names>E</given-names></name><name><surname>Bosi</surname><given-names>E</given-names></name><name><surname>Chiumello</surname><given-names>G</given-names></name><name><surname>Bonifacio</surname><given-names>E</given-names></name></person-group><article-title>Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM</article-title><source>Diabetologia</source><year>1996</year><volume>39</volume><fpage>1223</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">8897011</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onkamo</surname><given-names>P</given-names></name><name><surname>V&#x000e4;&#x000e4;n&#x000e4;nen</surname><given-names>M</given-names></name><name><surname>Karvonen</surname><given-names>M</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name></person-group><article-title>Worldwide increase in incidence of Type I diabetes &#x02013; the analysis of the data on published incidence trends</article-title><source>Diabetologia</source><year>1999</year><volume>42</volume><fpage>1395</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">10651256</pub-id><pub-id pub-id-type="doi">10.1007/s001250051309</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Djoulah</surname><given-names>S</given-names></name><name><surname>Khalil</surname><given-names>I</given-names></name><name><surname>Beressi</surname><given-names>JP</given-names></name><name><surname>Benhamamouch</surname><given-names>S</given-names></name><name><surname>Bessaoud</surname><given-names>K</given-names></name><name><surname>Deschamps</surname><given-names>I</given-names></name><name><surname>Degos</surname><given-names>L</given-names></name><name><surname>Hors</surname><given-names>J</given-names></name></person-group><article-title>The HLA-DR-B1*0405 haplotype is most strongly associated with IDDM in Algerians</article-title><source>Eur J Immunogenet</source><year>1992</year><volume>19</volume><fpage>381</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">1477090</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>H</given-names></name><name><surname>Howson</surname><given-names>JM</given-names></name><name><surname>Esposito</surname><given-names>L</given-names></name><name><surname>Heward</surname><given-names>J</given-names></name><name><surname>Snook</surname><given-names>H</given-names></name><name><surname>Chamberlain</surname><given-names>G</given-names></name><name><surname>Rainbow</surname><given-names>DB</given-names></name><name><surname>Hunter</surname><given-names>KM</given-names></name><name><surname>Smith</surname><given-names>AN</given-names></name><name><surname>Di Genova</surname><given-names>G</given-names></name><name><surname>Heer</surname><given-names>MH</given-names></name><name><surname>Dahlman</surname><given-names>I</given-names></name><name><surname>Payne</surname><given-names>F</given-names></name><name><surname>Smyth</surname><given-names>D</given-names></name><name><surname>Lowe</surname><given-names>C</given-names></name><name><surname>Twells</surname><given-names>RC</given-names></name><name><surname>Howlett</surname><given-names>S</given-names></name><name><surname>Healy</surname><given-names>B</given-names></name><name><surname>Nutland</surname><given-names>S</given-names></name><name><surname>Rance</surname><given-names>HE</given-names></name><name><surname>Everett</surname><given-names>V</given-names></name><name><surname>Smink</surname><given-names>LJ</given-names></name><name><surname>Lam</surname><given-names>AC</given-names></name><name><surname>Cordell</surname><given-names>HJ</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Bordin</surname><given-names>C</given-names></name><name><surname>Hulme</surname><given-names>J</given-names></name><name><surname>Motzo</surname><given-names>C</given-names></name><name><surname>Cucca</surname><given-names>F</given-names></name><name><surname>Hess</surname><given-names>JF</given-names></name><name><surname>Metzker</surname><given-names>ML</given-names></name><name><surname>Rojers</surname><given-names>J</given-names></name><name><surname>Gregory</surname><given-names>S</given-names></name><name><surname>Allahabadia</surname><given-names>A</given-names></name><name><surname>Nithiyananthan</surname><given-names>R</given-names></name><name><surname>Tuomilehto-Wolf</surname><given-names>E</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Bingley</surname><given-names>P</given-names></name><name><surname>Gillespie</surname><given-names>KM</given-names></name><name><surname>Undlien</surname><given-names>DE</given-names></name><name><surname>Ronningen</surname><given-names>KS</given-names></name><name><surname>Guja</surname><given-names>C</given-names></name><name><surname>Ionescu-Tirgoviste</surname><given-names>C</given-names></name><name><surname>Savage</surname><given-names>DA</given-names></name><name><surname>Maxwell</surname><given-names>AP</given-names></name><name><surname>Carson</surname><given-names>DJ</given-names></name><name><surname>Patterson</surname><given-names>CC</given-names></name><name><surname>Franklyn</surname><given-names>JA</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Peterson</surname><given-names>LB</given-names></name><name><surname>Wicker</surname><given-names>LS</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Gough</surname><given-names>SC</given-names></name></person-group><article-title>Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease</article-title><source>Nature</source><year>2003</year><volume>6939</volume><fpage>506</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">12724780</pub-id><pub-id pub-id-type="doi">10.1038/nature01621</pub-id></citation></ref><ref id="B27"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Dausset</surname><given-names>J</given-names></name></person-group><source>HLA Complexe majeur d'histocompatibilit&#x000e9; de l'homme</source><year>1989</year><publisher-name>Paris: Flammarion M&#x000e9;decine Sciences</publisher-name></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terasaki</surname><given-names>PI</given-names></name><name><surname>McClelland</surname><given-names>JD</given-names></name></person-group><article-title>Microdroplet assay of human serum cytotoxins</article-title><source>Nature</source><year>1964</year><volume>204</volume><fpage>998</fpage><lpage>00</lpage><pub-id pub-id-type="pmid">14248725</pub-id></citation></ref><ref id="B29"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Carpentier</surname><given-names>A</given-names></name><name><surname>Farge</surname><given-names>D</given-names></name></person-group><source>Transplantation d'organes</source><year>1992</year><publisher-name>Paris: Flammarion M&#x000e9;decine Sciences</publisher-name></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vincenzo</surname><given-names>C</given-names></name><name><surname>Margherita</surname><given-names>C</given-names></name><name><surname>Graziella</surname><given-names>I</given-names></name><name><surname>Giuseppina</surname><given-names>S</given-names></name><name><surname>Fortunato</surname><given-names>M</given-names></name><name><surname>Vincenzo</surname><given-names>TL</given-names></name></person-group><article-title>Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura</article-title><source>Haematologica</source><year>1997</year><volume>82</volume><fpage>471</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">9299867</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>Ch</given-names></name><name><surname>Klouda</surname><given-names>PT</given-names></name><name><surname>Corr&#x000ea;a</surname><given-names>MC</given-names></name><name><surname>Vassali</surname><given-names>P</given-names></name><name><surname>Jeannet</surname><given-names>M</given-names></name></person-group><article-title>Isolation of B- and T-lymphocytes by nylon fiber columns</article-title><source>Tissue Antigens</source><year>1977</year><volume>9</volume><fpage>227</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">301671</pub-id></citation></ref><ref id="B32"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Dagnelie</surname><given-names>P</given-names></name></person-group><source>Th&#x000e9;orie et m&#x000e9;thodes statistiques: les m&#x000e9;thodes de l'inf&#x000e9;rence statistique</source><year>1975</year><publisher-name>Gembloux: A.S.B.L</publisher-name></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ipsen</surname><given-names>J</given-names></name></person-group><article-title>The ubiquitous 2 &#x000d7; 2 table, its parameters and their confidence limits</article-title><source>Scand J Soc Med</source><year>1984</year><volume>12</volume><fpage>121</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">6505659</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>KD</given-names></name><name><surname>Lewis</surname><given-names>RJ</given-names></name></person-group><article-title>What is confidence? Part 2: Detailed definition and determination of confidence intervals</article-title><source>Ann Emerg Med</source><year>1997</year><volume>30</volume><fpage>311</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">9287893</pub-id></citation></ref></ref-list></back></article>



